Dimensional Fund Advisors LP Reduces Stock Position in Enovis Corporation $ENOV

Key Points

• Dimensional Fund Advisors reduced its Enovis position by 8.5%, selling 236,014 shares and retaining 2.55 million shares worth approximately $57.9 million. Institutional investors collectively own 98.45% of the company.
• Analyst sentiment remains generally positive: Enovis has a consensus rating of “Moderate Buy” and an average price target of $41.86, despite mixed individual rating changes.
• Enovis recently exceeded quarterly expectations, reporting $0.89 in earnings per share and $589.15 million in revenue, up 5.4% year over year. Shares opened at $29.22, while the company continues to report a negative net margin.

Dimensional Fund Advisors LP trimmed its holdings in Enovis Corporation (NYSE:ENOV - Free Report) by 8.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,545,922 shares of the company's stock after selling 236,014 shares during the period. Dimensional Fund Advisors LP owned about 4.42% of Enovis worth $57,917,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ENOV. Rubric Capital Management LP bought a new stake in shares of Enovis in the third quarter worth $83,435,000. AQR Capital Management LLC increased its position in shares of Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company's stock worth $15,627,000 after purchasing an additional 434,646 shares during the last quarter. Paradigm Capital Management Inc. NY raised its stake in shares of Enovis by 41.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company's stock valued at $34,913,000 after purchasing an additional 326,900 shares in the last quarter. ExodusPoint Capital Management LP raised its stake in shares of Enovis by 163.4% in the 4th quarter. ExodusPoint Capital Management LP now owns 508,971 shares of the company's stock valued at $13,559,000 after purchasing an additional 315,711 shares in the last quarter. Finally, Soleus Capital Management L.P. bought a new position in shares of Enovis during the second quarter worth about $9,878,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Enovis

In related news, insider Oliver Engert purchased 1,200 shares of the company's stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider owned 51,840 shares of the company's stock, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders purchased 4,200 shares of company stock worth $92,084 over the last three months. 2.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on ENOV shares. Zacks Research upgraded Enovis from a "strong sell" rating to a "hold" rating in a research note on Wednesday. UBS Group reaffirmed a "buy" rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a report on Tuesday. Weiss Ratings upgraded Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 21st. BMO Capital Markets assumed coverage on Enovis in a report on Wednesday, July 8th. They issued an "outperform" rating and a $29.00 price target for the company. Finally, Wall Street Zen raised Enovis from a "hold" rating to a "buy" rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $41.86.

Enovis Trading Down 0.3%

NYSE ENOV opened at $29.22 on Friday. Enovis Corporation has a one year low of $19.14 and a one year high of $34.28. The company has a 50-day simple moving average of $24.06 and a 200-day simple moving average of $23.82. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The firm has a market capitalization of $1.68 billion, a PE ratio of -1.47 and a beta of 1.39.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts' consensus estimates of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the prior year, the firm earned $0.81 EPS. The company's revenue for the quarter was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts forecast that Enovis Corporation will post 3.12 earnings per share for the current year.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.